Form 4 for MDGL MADRIGAL PHARMACEUTICALS, INC.
Accepted 2023-09-13 00:00:00 ET · period of report 2023-09-11 · accession 0000950170-23-047950 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-13 | 2023-09-11 | MDGL | Sibold William John | Pres, CEO, Dir | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
| D | 2023-09-13 | 2023-09-11 | MDGL | Sibold William John | Pres, CEO, Dir | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-11 | A | A | 50,000 | $0.00 | 50,000 | D | — | — | |
| 2 | Derivative | Performance Restricted Stock Units | 2023-09-11 | A | A | 50,000 | $0.00 | 50,000 | D | — · — to — | 50,000 Common Stock | (F2) Represents a grant of performance-based restricted stock units, which represent the contingent right to receive a number of shares of the Issuer's common stock that is between 0% and 300% of the target amount of units, depending on the Issuer's achievement of significant sustained stock price appreciation hurdles over a five-year period and which may settle on the 4th, 5th and 6th anniversaries of the grant date, depending on the date of vesting and performance level achieved. The number of shares of common stock reported assumes a target that corresponds to a 100% payout level. |